PODD Insulet
- 175.570
- -8.710-4.73%
Insulet News
Market Buzz: Insulet Corporation's (PODD) Stock Soars On Analyst Upgrade
Following an upgraded recommendation by an esteemed analyst firm, the shares of Insulet Corporation (NASDAQ: PODD) exhibited a noteworthy upsurge on the US stock market charts on Tuesday. Wrapping up the trading session, shares of Insulet (PODD) surged by 4.47%, or $7.88, to reach $184.28. On Tuesday, Wolfe Research upgraded its rating for Insulet (PODD) ...
Wolfe Raises Insulet to Outperform, Cites Increasing Market Share
Express News | Insulet Shares Are Trading Higher After Wolfe Research Upgraded the Stock From Peer Perform to Outperform
4 Analysts Assess Insulet: What You Need To Know
During the last three months, 4 analysts shared their evaluations of Insulet (NASDAQ:PODD), revealing diverse outlooks from bullish to bearish.The following table summarizes their recent ratings, shed
Insulet's 2023 Sustainability Report Highlights Commitment to Product Accessibility and Responsible Growth
Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today released its 2023 Sustainability Report, which describes
Insulet Raised to Outperform From Peer Perform by Wolfe Research
Insulet Raised to Outperform From Peer Perform by Wolfe Research
Insulet Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/07/2024 13.38% Wolfe Research → $200 Upgrades Peer Perform → Outperform 02/26/2024 20.75% Barclays $214
Wolfe Research Upgrades Insulet to Outperform From Peer Perform, Price Target Is $200
Wolfe Research Upgrades Insulet to Outperform From Peer Perform, Price Target is $200.
Insulet's Market Dominance and Growth Catalysts Prompt 'Buy' Rating
Investing in Insulet (NASDAQ:PODD) Five Years Ago Would Have Delivered You a 72% Gain
While Insulet Corporation (NASDAQ:PODD) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 13% in the last quarter. But at
Insulet (PODD) Rises Higher Than Market: Key Facts
DexCom, Insulet, Tandem Seen Benefitting the Most in Diabetes Survey - Wells Fargo
Insulet (PODD) Outperforms Broader Market: What You Need to Know
Top High Growth Investment Ratio Stocks From Each Sector - GS
Estimating The Fair Value Of Insulet Corporation (NASDAQ:PODD)
Key Insights The projected fair value for Insulet is US$182 based on 2 Stage Free Cash Flow to Equity Current share price of US$166 suggests Insulet is potentially trading close to its fair value
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals.
Abbott (ABT) Q1 Earnings Beat Estimates, Margins Contract
Earnings Growth Outpaced the Impressive 16% CAGR Delivered to Insulet (NASDAQ:PODD) Shareholders Over the Last Five Years
Will Insulet (PODD) Beat Estimates Again in Its Next Earnings Report?
Insulet (PODD) Stock Moves -0.34%: What You Should Know
Analysis
Price Target
No Data
